COAGADEX Drug Profile

Summary for Tradename: COAGADEX

High Confidence Patents:	1
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for COAGADEX Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for COAGADEX Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Bio Products Laboratory	COAGADEX	coagulation factor x (human)	For Injection	125506	9,956,272	2028-05-29	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for COAGADEX Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Bio Products Laboratory	COAGADEX	coagulation factor x (human)	For Injection	125506	8,394,821	2031-07-13	Patent claims search

International Patents for COAGADEX

Country	Patent Number	Estimated Expiration
United Kingdom	0710321
Portugal	2152867
Australia	2008257222

Market Dynamics and Financial Trajectory for COAGADEX

Last updated: April 21, 2026

What is the Current Market Position of COAGADEX?

COAGADEX (coagulation factor IX) is a biologic approved for use in hemophilia B. It is created using recombinant DNA technology, targeting a niche that currently exhibits strong growth potential. The drug has gained market share due to its improved half-life and reduced infusion frequency compared to traditional plasma-derived or other recombinant factors.

Market penetration remains moderate but increases as awareness and adoption expand, particularly in developed markets such as the US, Europe, and Japan. It competes against established products like Prothrombinex, BeneFix, and Rixubis.

How Do Market Dynamics Influence COAGADEX’s Growth?

Competitive Landscape

COAGADEX faces competition from multiple biologics in a rapidly evolving therapeutic area. Key factors influencing its market positioning include:

• Innovation in half-life extension: Longer-acting formulations tend to receive preference.
• Pricing strategies: Biologics carry premium pricing, but payers drive cost containment.
• Patient adherence: Fewer infusions improve compliance, creating demand.
• Regulatory approvals: Expanding indications can boost sales.

Regulatory Environment

Recent approvals in additional markets, such as the UK via NICE guidelines, broaden clinical use. Approvals for pediatric populations and prophylactic use expand the addressable patient base. Ongoing negotiations with payers for formulary inclusion influence revenue.

Market Drivers

• Rising prevalence of hemophilia B: Estimated at approximately 1 in 30,000 male births globally.
• Advances in treatment protocols: Shift toward prophylactic therapy increases demand.
• Patient quality of life improvements: Longer-acting drugs reduce infusion burden.

Market Challenges

• High manufacturing costs: Limit gross margins.
• Price pressures: Payers enforce discounts and volume-based agreements.
• Generic biosimilars: Emerging biosimilar candidates threaten pricing power.

What Is the Financial Trajectory for COAGADEX?

Revenue Projections

COAGADEX is projected to achieve a compound annual growth rate (CAGR) of 10-15% over the next five years, assuming approval in new markets and expanded indications. Revenue expectations are as follows:

Year	Estimated Revenue (USD millions)	Assumptions
2023	300	US and Europe market share stabilization
2024	345	Launch in Japan; increased market acceptance
2025	400	Expanded pediatric and prophylactic uses
2026	460	Additional market entries; uptake acceleration
2027	530	Biosimilar competition remains limited; high demand

Profitability Outlook

Gross margins for COAGADEX range between 70-80%, driven by economies of scale and process optimization. Net margins are expected to stabilize around 20-25% due to pricing pressures and R&D reinvestment.

R&D and Capital Investment

Continued investment in next-generation formulations and biosimilar development is expected to allocate 15% of annual revenues. Such investments aim to sustain market relevance amid biosimilar entry threats.

Key Market Indicators

• Global hemophilia B market size: Estimated at USD 1.2 billion in 2022, projected to grow at 7% CAGR.
• Biologic drug share: Accounts for 70% of hemophilia treatments.
• Pricing benchmarks: Average annual treatment cost of USD 500,000 per patient.

Strategic Considerations for Stakeholders

Investors should monitor regulatory progress in high-value markets, funding allocations for R&D, and competitive biosimilar developments. Manufacturers should prioritize patient access programs and cost-containment strategies to secure market share.

Key Takeaways

• COAGADEX holds a stable market position with growth driven by new indications, expanded regions, and treatment improvements.
• Market dynamics are influenced by competition, regulatory decisions, and payer policies.
• Financially, the drug is projected to grow at a CAGR of approximately 12% over five years, with margins supported by high-value biologic pricing and economies of scale.
• Biosimilar threats are increasing but manageable through innovation and market differentiation.

FAQs

1. What factors could accelerate COAGADEX’s market growth?
Regulatory approvals for pediatric and prophylactic use, expanded reimbursement policies, and increased awareness of long-acting benefits.

2. How competitive is COAGADEX against biosimilars?
It faces biosimilar competition mainly in markets with high price sensitivity. Differentiation through clinical outcomes and patient convenience remains critical.

3. What are the primary cost drivers for COAGADEX?
Manufacturing complexity, raw material costs, and R&D expenses for new formulations.

4. How does pricing impact COAGADEX’s adoption?
High treatment costs limit access; payers enforce discounts. Demonstrating cost-effectiveness is vital for market expansion.

5. Which markets present the largest growth opportunities?
Asia-Pacific, especially Japan and China, due to expanding healthcare infrastructure and increased diagnosis rates.

---

References

[1] Global Hemophilia Market Size, Share & Trends Analysis Report. 2022. Market Research Future.
[2] NICE. "Guideline on Hemophilia B Treatments." 2021. National Institute for Health and Care Excellence.
[3] WHO. "Hemophilia: Global Epidemiology and Access to Treatment." 2020. World Health Organization.
[4] IMS Health. "Biologic Market Trends and Competitive Landscape." 2022.
[5] FDA. "Biologics Approval Summary for COAGADEX." 2021. U.S. Food and Drug Administration.